Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 9,463 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 9,463 shares of the company’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $30.00, for a total value of $283,890.00. Following the transaction, the insider directly owned 299,368 shares in the company, valued at $8,981,040. This represents a 3.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, March 17th, Soleil Boughton sold 4,812 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.69, for a total value of $118,808.28.

Hims & Hers Health Price Performance

Shares of NYSE HIMS traded down $0.81 during trading on Wednesday, hitting $28.95. 32,054,280 shares of the company were exchanged, compared to its average volume of 34,470,430. The company has a market cap of $6.60 billion, a price-to-earnings ratio of 56.77, a PEG ratio of 2.95 and a beta of 2.32. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43. The firm’s fifty day moving average price is $20.20 and its 200 day moving average price is $31.76. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same quarter last year, the firm posted $0.11 EPS. The business’s revenue was up 28.4% compared to the same quarter last year. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Hims & Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after acquiring an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the first quarter valued at $30,000. EverSource Wealth Advisors LLC boosted its stake in shares of Hims & Hers Health by 273.7% during the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares during the last quarter. Amundi increased its position in Hims & Hers Health by 5.3% during the 2nd quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after purchasing an additional 522 shares in the last quarter. Finally, California Public Employees Retirement System increased its position in Hims & Hers Health by 9.5% during the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock worth $16,880,000 after purchasing an additional 29,471 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Truist Financial reissued a “hold” rating and set a $18.00 price target (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Morgan Stanley lowered their target price on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Finally, BTIG Research cut Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $31.86.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: HIMS is expanding into perimenopause and menopause treatment options to address rising U.S. demand for hormone therapy and strained estrogen‑patch supplies—this broadens the women’s health product set and reduces reliance on any single category. Read More.
• Positive Sentiment: Investor momentum around HIMS’ peptide program (and reports of a potential Novo Nordisk tie and FDA peptide developments) has been a key bullish catalyst, driving the large one‑week rally that preceded today’s pullback. Read More.
• Neutral Sentiment: HIMS is investing in a data‑driven, personalized care platform (adding labs and multi‑cancer testing) to increase customer lifetime value—strategic but longer‑term and not an immediate revenue catalyst. Read More.
• Neutral Sentiment: Analyst coverage is mixed: several price‑target moves and a consensus “Hold” bias mean broker commentary could amplify short‑term swings but currently offers no clear directional push. Read More.
• Negative Sentiment: Insider selling: CFO Oluyemi Okupe sold sizable blocks of shares under a pre‑arranged 10b5‑1 plan in mid‑April (~54,927 shares across dates), which can weigh on sentiment despite being pre‑planned. Read More.
• Negative Sentiment: Competitive risk: Amazon launched a GLP‑1 weight‑loss program, raising the prospect of a large new entrant in prescription telehealth and ongoing obesity care—this increases pressure in HIMS’ high‑growth medication categories. Read More.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.